KVUE

Kenvue Declares Quarterly Cash Dividend

Retrieved on: 
Giovedì, Gennaio 25, 2024
Cosmetics, Medical Supplies, Retail, Health, Home Goods, Pharmaceutical, Inc., KVUE

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a dividend payable in the first quarter of $0.20 per share on the Company’s common stock.

Key Points: 
  • Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a dividend payable in the first quarter of $0.20 per share on the Company’s common stock.
  • The first quarter dividend is payable on February 28, 2024 to shareholders of record as of the close of business on February 14, 2024.

Kenvue to Announce Fourth Quarter and Full Year 2023 Results on February 8, 2024

Retrieved on: 
Venerdì, Gennaio 5, 2024
Retail, Home Goods, General Health, Health, Webcast, ID, KVUE, Inc.

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the fourth quarter and full year ending December 31, 2023, before market open on February 8, 2024.

Key Points: 
  • Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the fourth quarter and full year ending December 31, 2023, before market open on February 8, 2024.
  • The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results.
  • The conference call can be accessed by dialing 888-660-5501 from the U.S. or 646-960-0416 from international locations.
  • A live webcast of the conference call will be available at https://investors.kenvue.com .

KVUE DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kenvue Inc. Investors to Secure Counsel Before Important December 8 Deadline in Securities Class Action First Filed by the Firm - KVUE

Retrieved on: 
Sabato, Dicembre 2, 2023
Titan, Phenylephrine, Court, Register, KVUE, Plaintiff, Prospectus, Advertising, Tobacco

WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

KVUE DEADLINE ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Kenvue Inc. Investors to Secure Counsel Before Important December 8 Deadline in Securities Class Action First Filed by the Firm - KVUE

Retrieved on: 
Giovedì, Novembre 30, 2023
Titan, Phenylephrine, Court, Register, KVUE, Plaintiff, Prospectus, Advertising, Tobacco

WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

KVUE FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Kenvue, Inc. (KVUE) Investors with Substantial Losses to Contact its Attorneys Before Dec. 8th Deadline in Securities Class Action

Retrieved on: 
Giovedì, Dicembre 7, 2023
FDA, IPO, KVUE, Person, Hagens Berman, Risk, Phenylephrine, Pharmaceutical industry

On or around Sept. 12, 2023, the FDA published a briefing document announcing that it was convening an advisory committee to discuss efficacy data available for orally administered phenylephrine as a nasal decongestant.

Key Points: 
  • On or around Sept. 12, 2023, the FDA published a briefing document announcing that it was convening an advisory committee to discuss efficacy data available for orally administered phenylephrine as a nasal decongestant.
  • “We’re focused on investors’ losses and investigating whether Kenvue adequately disclosed commercial risks related to its products containing PE,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.
  • For more information, call Reed Kathrein at 844-916-0895 or email [email protected] .

KENVUE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Kenvue To Contact Him Directly To Discuss Their Options

Retrieved on: 
Giovedì, Dicembre 7, 2023
Risk, Johnson & Johnson, Phenylephrine, LLP, FDA, Court, Complaint, KVUE, Advertising, Prospectus, Defendant, Woman, Security (finance)

NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and reminds investors of the December 8, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.
  • Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Kenvue’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Deadline in 2 Days for Kenvue Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Kenvue Inc. (KVUE) Investors of Filing Deadline in Class Action Lawsuit

Retrieved on: 
Mercoledì, Dicembre 6, 2023
Lead, Johnson & Johnson, LLP, Court, CLASS, News, COPY, Insurance, KVUE, IPO, District court

The action charges Kenvue with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges Kenvue with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of Kenvue’s materially misleading statements and omissions to the public, Kenvue’s investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages Kenvue investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The class action complaint against Kenvue, Hammond v. Kenvue Inc., et al., Case No.

KVUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Kenvue Inc. Investors with Losses to Contact the Firm!

Retrieved on: 
Mercoledì, Dicembre 6, 2023
Risk, Phenylephrine, Person, Court, NaN, Register, Complaint, KVUE, Prospectus

Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/kvue .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/kvue .
  • When the true details entered the market, the lawsuit claims that investors suffered damages.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

KENVUE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Kenvue Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Mercoledì, Dicembre 6, 2023
Telephone, Risk, Phenylephrine, Person, Court, Register, P.C, KVUE, IPO, Prospectus, District court

Investors have until December 8, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until December 8, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • If you purchased or otherwise acquired Kenvue shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected] , telephone at (212) 355-4648, or by filling out this contact form .
  • There is no cost or obligation to you.

KVUE DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Kenvue Inc. Investors to Secure Counsel Before Important December 8 Deadline in Securities Class Action Commenced by the Firm – KVUE

Retrieved on: 
Martedì, Dicembre 5, 2023
Titan, Phenylephrine, Court, Register, KVUE, Advertising, Prospectus, Tobacco

WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.